This is an automatically translated article.
Paclirich drug has the main ingredient is Paclitaxel, is prepared in the form of a concentrated solution for injection and packed in a box of 1 bottle of 17ml. This drug belongs to the group of anti-cancer drugs and acts on the immune system. The following is information about the uses, dosage and precautions when using Paclirich.
1. What is the use of Paclirich?
Paclirich drug has the main ingredient is Paclitaxel, is prepared in the form of a concentrated solution for injection and packed in a box of 1 bottle of 17ml.
Paclirich is indicated for use in the following cases:
Treatment of ovarian carcinoma:
Used as first-line therapy for advanced ovarian cancer or residual tumor larger than 1cm after surgery, the drug is used in combination with cisplatin; Used as follow-up therapy in metastatic ovarian cancer, after failure of conventional treatment such as platinum derivatives. Treatment of breast carcinoma:
With adjuvant treatment of early cancer, positive lymph node test results, consecutive use after a regimen containing doxorubicine; With treatment of metastatic breast cancer that has ceased to be effective with standard treatment or relapsed after adjuvant therapy. Unless contraindicated, usually previous treatments contain anthracyclines. Treatment of non-small cell lung cancer
First-line indication for the treatment of patients with non-small cell lung cancer, using paclitaxel in combination with cisplatine, in the inoperable stage and/or radiotherapy;
In addition, the ingredient Paclitaxel is also used to treat AIDS-related Kaposi's cancer.
2. Dosage and how to use Paclirich
2.1. Dosage All patients must be pretreated to avoid hypersensitivity reactions.
Pre-treatment includes dexamethasone 20 mg/day orally 6-12 hours before paclitaxel, diphenhydramine or the equivalent of 50 mg IV 30-60 minutes before paclitaxel and cimetidine 300 mg or ranitidine 50 mg IV 30 -60 minutes before taking Paclitaxel.
Paclitaxel should not be administered until the neutrophil count has reached at least 1,500 cells/mm3 and the platelet count has reached at least 100,000 cells/mm3.
Patients with severe neutropenia or peripheral neuropathy must take a 20% dose reduction in subsequent cycles.
Advanced ovarian cancer: The recommended dose for first-line therapy is 135 mg/m2 infused over 24 hours, followed by cisplatin and repeated every 3 weeks. Alternatively, a dose of 175 mg/m2 infusion over 3 hours can be used, followed by treatment with cisplatin every 3 weeks. In second-line therapy, the recommended dose for monotherapy is 135 or 175 mg/m2 infused over 3 hours, repeated every 3 weeks. Breast cancer: Paclitaxel 175 mg/m2 infusion over 3 hours every 3 weeks is recommended for adjuvant therapy - with 4 courses in second-line monotherapy and in first-line therapy in combination with trastuzumab, paclitaxel given administered on the next day after trastuzumad or immediately after trastuzumad if well tolerated. In first-line therapy in combination with doxorubicin, Paclitaxel 220 mg/m2 is infused over 3 hours every 3 weeks, this dose is given 24 hours after doxorubicin. Non-small cell lung cancer: The recommended dose is paclitaxel 135 mg/m2 infused over 24 hours or 175 mg/m2 infused over 3 hours, followed by cisplatin and repeated every 3 weeks. 2.2. How to use Paclirich is given into the body by intravenous infusion.
3. Notes when using the drug Paclirich
3.1. Contraindications Patients with a history of hypersensitivity to the drug or to its components including cremophor ELP in the formulation; Patients with neutropenia below 1,500 cells/mm3; Women who are pregnant or breastfeeding; The patient has obvious motor neuron disease. 3.2. Side effects In the process of using paclirich for treatment, patients may experience some health problems such as bone marrow depression, low blood pressure, increased liver enzymes, muscle and joint pain, digestive disorders, hair loss, peripheral neuropathy.
3.3. Caution In patients with disorders or diseases that impair liver function, the dose should be reduced. Paclitaxel is not recommended for use in cases where transaminases are increased 10 times the upper limit of normal, or bilirubin is greater than 7.5 mg/100 ml or 5 times the upper limit of normal; Use with caution in patients with heart disease; In the preparation with the excipient is cremophor EL, which is more likely to cause anaphylactoid-type responses due to the high release of histamine in people who are hypersensitive to cremophor EL. Therefore, patients need to take anaphylaxis prophylaxis before treatment and need to be prepared to deal with anaphylactic reactions when they occur; Use with caution in patients with a history of peripheral neuropathy (chemotherapy or diabetic neuropathy); When multiple drugs are administered sequentially, taxane derivatives (paclitaxel, docetaxel) should be administered before platinum derivatives to reduce the risk of myelosuppression; The elderly are at increased risk of toxicity (neuropathy, agranulocytosis). Paclirich medicine has the main ingredient is Paclitaxel, is prepared in the form of a concentrated solution for injection and packed in a box of 1 bottle of 17ml. This drug belongs to the group of anti-cancer drugs and acts on the immune system. Patients need to strictly follow the instructions of the doctor and medical staff to ensure the effectiveness of treatment and avoid unwanted side effects.
Follow Vinmec International General Hospital website to get more health, nutrition and beauty information to protect the health of yourself and your loved ones in your family.
Please dial HOTLINE for more information or register for an appointment HERE. Download MyVinmec app to make appointments faster and to manage your bookings easily.
